Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose open-label Xeomin study for glabellar frown lines
2006-005342-36Phase 3Completed
- Sponsor
- Merz
- Start
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in glabellar furrowing, sponsored by Merz. Primary endpoint: Safety. Started Mar 2007; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2006-005342-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005342-36.